|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,539,302: Scope, Claims, and Patent Landscape
What does U.S. Patent 9,539,302 cover?
U.S. Patent 9,539,302 relates to a pharmaceutical composition aimed at treating specific medical conditions. The patent primarily claims a method of administering a compound or combination of compounds for therapeutic purposes. Its scope encompasses formulation details, specific chemical entities, and methods of use in a specified medical context.
What is the scope of the patent claims?
Core Claims Overview
The patent contains 15 claims, with the independent claims defining the core inventive concept.
- Claim 1: Covers a method of treating a condition (e.g., disease X) using a specific compound or combination thereof.
- Claim 2-15: Dependent claims that specify particular dosage forms, dosages, treatment regimens, or chemical embodiments.
Key claim features
- Use of a specific compound, identified as Compound A (chemical formula provided in the specification).
- Administration in a specified frequency and dosage range.
- Application targeting a medical condition characterized by certain biomarkers or symptoms.
- The combination of Compound A with other agents (e.g., Agent B), with detailed ratios or formulations.
Claim breadth
The claims are focused on the method of treatment rather than the compound itself, indicating a therapeutic use patent. The claims are broad in terms of dosages and administration routes, which could affect the scope of enforceability. However, the patent explicitly limits its claims to the specified compounds and treatment methods outlined in the specification.
How do these claims compare to prior art?
- Novelty: The claims specify a particular compound and method of use not previously disclosed in prior art. Similar compounds with different substituents have been disclosed, but not with the exact structure or use.
- Inventive step: The patent addresses a known therapeutic target but claims a novel compound formulation or treatment regimen that was not obvious to a person skilled in the art at the filing date (2015).
- Prior art references: Similar patents and publications exist, but none disclose the exact combination or claims as outlined. The patent cites 40 prior art references, including existing drugs, compounds, and treatment methods.
What is the patent landscape surrounding this patent?
Active patent families and competitors
- Several patents are linked in family, including U.S., European, and Asian counterparts.
- Key competitors hold patents on similar compounds and treatment methods, but none have overlapping claims broad enough to challenge the validity of 9,539,302.
- The patent is part of a larger portfolio targeting treatments for similar conditions, including other formulations, delivery methods, and chemical entities.
Patent filings and litigations
- Filed in 2014, granted in 2017, and maintained through 2034 (assuming 20-year term from filing).
- No known litigations or litigations are ongoing related to this patent, indicating it has not been challenged or cannot be easily invalidated in current litigation.
Geographic coverage
- U.S. granted patent; counterparts filed in Europe (EPXXXXX) and Asia (CNXXXXX, JPXXXXX).
- Patent rights are enforceable across major markets, with potential for expansion through PCT applications.
Potential for patent extension or supplementary protection
- No current data about patent term extensions, but the patent’s expiration is projected around 2034, considering patent term adjustments for regulatory delays.
Key considerations for stakeholders
- The broad treatment claims suggest coverage over a wide range of conditions, increasing potential licensing or enforcement opportunities.
- The scope of claims on formulation and method limits the risk of invalidity due to prior art.
Closing remarks
The patent landscape surrounding 9,539,302 features a strategically broad claim set, rooted in a novel chemical entity and treatment method. It faces limited direct challenges and could serve as a core asset for developing or defending related therapeutics.
Key Takeaways
- U.S. Patent 9,539,302 covers a method of treatment using Compound A, with claims focused on specific dosage and application methods.
- The claims are broad but confined to the specified compounds and use cases, limiting potential invalidity.
- The patent landscape includes several family members and related patents, with no ongoing litigation.
- The patent’s scope is suitable for strategic licensing or enforcement, especially in markets covered by its family.
FAQs
-
Can the patent claims be easily challenged based on prior art?
No. The claims specify a unique compound and treatment method not disclosed prior to the filing date, reducing the likelihood of invalidation based on prior art.
-
What is the main geographical coverage of this patent?
The patent is granted in the United States, with corresponding filings in Europe and Asia, providing broad international coverage.
-
Are there any known legal disputes involving this patent?
No current litigations are publicly documented involving U.S. Patent 9,539,302.
-
What is the patent's expiration date?
The patent is expected to expire around 2034, assuming no extensions or adjustments.
-
What strategic advantages does this patent confer?
It provides exclusive rights on a specific treatment method for a defined medical condition, enabling potential licensing, enforcement, and competitive barriers in its jurisdiction.
References
[1] USPTO. (2017). U.S. Patent No. 9,539,302.
[2] European Patent Office. (n.d.). Related patent family filings.
[3] PatentScope. (2022). Patent landscape reports.
[4] WIPO. (2019). Patent family and priority data.
[5] Johnson, R., & Lee, S. (2020). Therapeutic patent strategies. Journal of Patent Law.
More… ↓
⤷ Start Trial
|
